Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy
Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk
Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy
Objective: We aim to evaluated the effect of rehabilitation therapy on the motor symptoms and activities of daily living in patients with MSA using an…TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein – A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy
Objective: The objective of the TOPAS-MSA study is to assess the safety and efficacy of emrusolmin (anle138b/TEV-56286), an orally bioavailable small molecule targeting aggregated α-synuclein,…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Objective: Assess brain volume changes in patients with multiple system atrophy (MSA) over one year. Background: Identifying disease progression biomarkers is crucial for advancing MSA…Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial
Objective: To understand patient and caregiver preferences and perceptions of a proposed clinical trial design for an interventional drug targeting Multiple System Atrophy. Background: Stakeholders…
- 1
- 2
- 3
- …
- 7
- Next Page »